• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经氟代脱氧葡萄糖正电子发射断层扫描(FDG-PET)鉴定的,来自去势抵抗性前列腺腺癌的孤立性、前列腺特异性膜抗原(PSMA)阴性阴茎转移瘤。

Isolated, PSMA-negative penile metastasis from castration resistant prostate adenocarcinoma, identified by FDG-PET.

作者信息

Chau Matthew, Swarbrick Nicole, Lee Sunny

机构信息

Department of Urology, Royal Perth Hospital, Perth, WA, Australia.

Department of Anatomical Pathology, Path West Laboratory Medicine, Perth, WA, Australia.

出版信息

Urol Case Rep. 2022 Dec 12;46:102300. doi: 10.1016/j.eucr.2022.102300. eCollection 2023 Jan.

DOI:10.1016/j.eucr.2022.102300
PMID:36568633
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9771717/
Abstract

Penile metastases are a rare entity and are associated with widespread metastatic disease. It is associated with significant morbidity with a poor prognosis. There have been few case reports about metastatic prostate adenocarcinoma to the penis. Diagnosis is often clinical, however, the use of PSMA PET has a high sensitivity. We report the first case of metastatic castration resistant prostate cancer with an isolated penile metastatic site. This was not identified on conventional staging or PSMA PET, but using FDG PET. A radical penectomy was performed with ongoing survival.

摘要

阴茎转移瘤是一种罕见的疾病,与广泛的转移性疾病相关。它与严重的发病率和不良预后相关。关于前列腺腺癌转移至阴茎的病例报告很少。诊断通常依靠临床症状,然而,使用前列腺特异性膜抗原(PSMA)正电子发射断层扫描(PET)具有很高的敏感性。我们报告了首例孤立性阴茎转移灶的去势抵抗性前列腺癌转移病例。该病例在传统分期或PSMA PET检查中均未发现,但通过氟代脱氧葡萄糖(FDG)PET检查得以确诊。患者接受了根治性阴茎切除术,目前仍存活。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e71a/9771717/3fe2e365a3ef/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e71a/9771717/89a47e052fa7/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e71a/9771717/3fe2e365a3ef/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e71a/9771717/89a47e052fa7/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e71a/9771717/3fe2e365a3ef/gr2.jpg

相似文献

1
Isolated, PSMA-negative penile metastasis from castration resistant prostate adenocarcinoma, identified by FDG-PET.经氟代脱氧葡萄糖正电子发射断层扫描(FDG-PET)鉴定的,来自去势抵抗性前列腺腺癌的孤立性、前列腺特异性膜抗原(PSMA)阴性阴茎转移瘤。
Urol Case Rep. 2022 Dec 12;46:102300. doi: 10.1016/j.eucr.2022.102300. eCollection 2023 Jan.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
Case Report: F-PSMA PET/CT May Improve the Clinical Management of Penile Metastases From Prostate Cancer.病例报告:F-PSMA PET/CT 可能改善前列腺癌阴茎转移的临床管理。
Front Oncol. 2021 May 13;11:683343. doi: 10.3389/fonc.2021.683343. eCollection 2021.
4
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.PSMA 和 FDG-PET 作为预测和预后生物标志物,用于比较 [Lu]Lu-PSMA-617 与卡巴他赛治疗转移性去势抵抗性前列腺癌(TheraP):一项随机、开放标签、2 期临床试验的生物标志物分析。
Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16.
5
Case Report: F-PSMA-1007 PET/CT Avid Solitary Penile Metastasis of Castration-Resistant Prostate Cancer With a PSA of 0.072 ng/ml.病例报告:F-PSMA-1007 PET/CT检测到的去势抵抗性前列腺癌孤立性阴茎转移,前列腺特异性抗原(PSA)为0.072 ng/ml 。
Front Oncol. 2022 Apr 20;12:881896. doi: 10.3389/fonc.2022.881896. eCollection 2022.
6
Dual-Tracer Positron-Emission Tomography Using Prostate-Specific Membrane Antigen and Fluorodeoxyglucose for Staging of Prostate Cancer: A Systematic Review.使用前列腺特异性膜抗原和氟脱氧葡萄糖的双示踪正电子发射断层扫描用于前列腺癌分期:一项系统评价。
Adv Urol. 2021 Aug 18;2021:1544208. doi: 10.1155/2021/1544208. eCollection 2021.
7
[Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.[镥]-PSMA-617 放射性核素治疗转移性去势抵抗性前列腺癌患者(LuPSMA 试验):一项单中心、单臂、2 期研究。
Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8.
8
Prostate penile metastasis: Incidence and imaging pattern on Ga-PSMA PET/CT.前列腺阴茎转移:Ga-PSMA PET/CT 的发生率和影像学模式。
J Med Imaging Radiat Oncol. 2020 Aug;64(4):499-504. doi: 10.1111/1754-9485.13052. Epub 2020 May 25.
9
The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.三示踪剂策略治疗转移性前列腺癌(3TMPO)研究方案。
BJU Int. 2022 Sep;130(3):314-322. doi: 10.1111/bju.15621. Epub 2021 Nov 11.
10
Results of a Prospective Phase 2 Pilot Trial of Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression.Lu-PSMA-617 治疗转移性去势抵抗性前列腺癌的前瞻性 2 期试验结果,包括治疗反应的影像学预测因子和进展模式。
Clin Genitourin Cancer. 2019 Feb;17(1):15-22. doi: 10.1016/j.clgc.2018.09.014. Epub 2018 Sep 27.

本文引用的文献

1
Patient with penile metastasis from prostate cancer and survival over 5 years: A case report with longitudinal evaluation using computed tomography and magnetic resonance imaging.前列腺癌阴茎转移患者生存超过5年:一例使用计算机断层扫描和磁共振成像进行纵向评估的病例报告
Radiol Case Rep. 2021 Mar 26;16(6):1255-1258. doi: 10.1016/j.radcr.2021.02.064. eCollection 2021 Jun.
2
Diagnostic value of F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative Ga-PSMA PET/CT.18F-FDG PET/CT 对生化复发前列腺癌且 Ga-PSMA PET/CT 阴性患者的诊断价值。
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2970-2977. doi: 10.1007/s00259-021-05221-6. Epub 2021 Feb 2.
3
Impact of Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
镓-PSMA PET 对前列腺癌患者管理的影响:系统评价和荟萃分析。
Eur Urol. 2018 Aug;74(2):179-190. doi: 10.1016/j.eururo.2018.03.030. Epub 2018 Apr 18.
4
Metastatic tumors of the penis: a report of 8 cases and review of the literature.阴茎转移性肿瘤:8例报告并文献复习
Medicine (Baltimore). 2015 Jan;94(1):e132. doi: 10.1097/MD.0000000000000132.